These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
244 related items for PubMed ID: 17321775
1. Serum procollagen type 1 amino-terminal propeptide (P1NP) as an early predictor of the growth response to growth hormone treatment: Comparison of intrauterine growth retardation and idiopathic short stature. Gascoin-Lachambre G, Trivin C, Brauner R, Souberbielle JC. Growth Horm IGF Res; 2007 Jun; 17(3):194-200. PubMed ID: 17321775 [Abstract] [Full Text] [Related]
2. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children. Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, DiNero G. Pediatr Res; 1994 Apr; 35(4 Pt 1):409-15. PubMed ID: 8047377 [Abstract] [Full Text] [Related]
3. Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature. Hughes IP, Harris M, Choong CS, Ambler G, Cutfield W, Hofman P, Cowell CT, Werther G, Cotterill A, Davies PS, Australasian Paediatric Endocrine Group (APEG). Clin Endocrinol (Oxf); 2012 Jul; 77(1):62-71. PubMed ID: 21950731 [Abstract] [Full Text] [Related]
4. [The effectiveness of recombinant growth hormone in height deficiency due to intrauterine growth retardation]. Vicens-Calvet E, Seijo G, Potau N, de los Llanos Moreno M, Carrascosa A. Med Clin (Barc); 1999 May 08; 112(16):601-5. PubMed ID: 10374174 [Abstract] [Full Text] [Related]
5. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Ranke MB, Lindberg A, Price DA, Darendeliler F, Albertsson-Wikland K, Wilton P, Reiter EO, KIGS International Board. Horm Res; 2007 May 08; 68(2):53-62. PubMed ID: 17228181 [Abstract] [Full Text] [Related]
7. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency. Gonc EN, Kandemir N. Clin Endocrinol (Oxf); 2007 May 08; 66(5):672-7. PubMed ID: 17381489 [Abstract] [Full Text] [Related]
8. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study. Lanes R, Gunczler P, Esaa S, Weisinger JR. Clin Endocrinol (Oxf); 2002 Dec 08; 57(6):725-30. PubMed ID: 12460321 [Abstract] [Full Text] [Related]
9. Does preterm birth influence the response to growth hormone treatment in short, small for gestational age children? de Kort SW, Willemsen RH, van der Kaay DC, Duivenvoorden HJ, Hokken-Koelega AC. Clin Endocrinol (Oxf); 2009 Apr 08; 70(4):582-7. PubMed ID: 19067725 [Abstract] [Full Text] [Related]
10. Serum aminoterminal propeptide of type III procollagen: a potential predictor of the response to growth hormone therapy. Tapanainen P, Risteli L, Knip M, Käär ML, Risteli J. J Clin Endocrinol Metab; 1988 Dec 08; 67(6):1244-9. PubMed ID: 3192681 [Abstract] [Full Text] [Related]
11. Growth hormone responsiveness: peak stimulated growth hormone levels and other variables in idiopathic short stature (ISS): data from the National Cooperative Growth Study. Moore WV, Dana K, Frane J, Lippe B. Pediatr Endocrinol Rev; 2008 Sep 08; 6(1):5-8. PubMed ID: 18806719 [Abstract] [Full Text] [Related]
12. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children. Crofton PM, Stirling HF, Schönau E, Kelnar CJ. Clin Endocrinol (Oxf); 1996 Apr 08; 44(4):385-94. PubMed ID: 8706304 [Abstract] [Full Text] [Related]
14. Diagnosis and growth hormone (GH) therapy in children with GH deficiency: experience in King Chulalongkorn Memorial Hospital, Thailand. Wacharasindhu S, Supornsilchai V, Aroonparkmongkol S, Srivuthana S. J Med Assoc Thai; 2007 Oct 08; 90(10):2047-52. PubMed ID: 18041422 [Abstract] [Full Text] [Related]
15. Insulin-like growth factor I and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, turner syndrome and born small for gestational age. Cutfield WS, Lundgren F. Horm Res; 2009 Jan 08; 71 Suppl 1():39-45. PubMed ID: 19153504 [Abstract] [Full Text] [Related]
16. Long-term monitoring of treatment with recombinant human growth hormone by serial determinations of type III procollagen-related antigens in serum. Danne T, Grüters A, Schnabel K, Burger W, L'Allemand D, Enders I, Helge H, Weber B. Pediatr Res; 1988 Feb 08; 23(2):167-71. PubMed ID: 3353159 [Abstract] [Full Text] [Related]
17. Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of idiopathic short stature (ISS). Park P, Cohen P. Growth Horm IGF Res; 2005 Jul 08; 15 Suppl A():S13-20. PubMed ID: 16039893 [Abstract] [Full Text] [Related]
18. Efficacy of combined treatment with growth hormone and gonadotropin releasing hormone analogue in children with poor prognosis of adult height. Toumba M, Bacopoulou I, Savva SC, Skordis N. Indian Pediatr; 2007 Jul 08; 44(7):497-502. PubMed ID: 17684302 [Abstract] [Full Text] [Related]
20. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma. Klepzig M, Jonas D, Oremek GM. Anticancer Res; 2009 Feb 08; 29(2):671-3. PubMed ID: 19331219 [Abstract] [Full Text] [Related] Page: [Next] [New Search]